12 Month Price Forecast For SRZN
Distance to SRZN Price Forecasts
SRZN Price Momentum
๐ค Considering Surrozen (SRZN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 2:58 PM UTC
SRZN Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, SRZN has a bullish consensus with a median price target of $38.50 (ranging from $32.00 to $45.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $10.00, the median forecast implies a 285.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yatin Suneja at Guggenheim, projecting a 350.0% upside. Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 220.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SRZN Analyst Consensus
SRZN Price Target Range
Latest SRZN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SRZN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 30, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $32.00 |
Jan 3, 2025 | Guggenheim | Yatin Suneja | Buy | Upgrade | $45.00 |
Nov 29, 2022 | JP Morgan | Eric Joseph | Underweight | Downgrade | $0.00 |
Nov 18, 2022 | Guggenheim | Yatin Suneja | Neutral | Downgrade | $0.00 |
Nov 17, 2022 | B of A Securities | Tazeen Ahmad | Underperform | Downgrade | $1.00 |
Oct 17, 2022 | JP Morgan | Eric Joseph | Neutral | Initiates | $0.00 |
May 27, 2022 | B of A Securities | Tazeen Ahmad | Neutral | Downgrade | $5.00 |
Oct 11, 2021 | B of A Securities | Buy | Initiates | $0.00 | |
Sep 15, 2021 | Guggenheim | Buy | Initiates | $0.00 | |
Sep 7, 2021 | Stifel | Buy | Initiates | $0.00 |
Stocks Similar to Surrozen, Inc.
The following stocks are similar to Surrozen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Surrozen, Inc. (SRZN) Financial Data
Surrozen, Inc. has a market capitalization of $32.50M with a P/E ratio of -0.5x. The company generates $10.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +12.3% and return on equity of -173.6%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Surrozen, Inc. (SRZN) Company Overview
About Surrozen, Inc.
Biotechnology company developing Wnt pathway therapeutics.
Surrozen, Inc. operates as a clinical stage biotechnology firm focused on discovering and developing drug candidates that modulate the Wnt pathway for tissue repair. The company generates revenue through collaborations and licensing agreements, such as its partnership with Boehringer Ingelheim, while advancing its own pipeline of antibody-based therapeutics targeting various diseases.
The company is currently advancing several products in clinical trials, including SZN-043 for severe liver diseases and SZN-413 for retinal vascular diseases. With a strong focus on the Wnt pathway, Surrozen aims to address unmet medical needs across multiple organ systems, positioning itself for potential future growth in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
42
CEO
Mr. Craig C. Parker M.B.A.
Country
United States
IPO Year
2021
Website
www.surrozen.comSurrozen, Inc. (SRZN) Latest News & Analysis
Surrozen, Inc. reports progress in its Phase 1b trial for SZN-043 in severe alcohol-associated hepatitis, with data expected in H1 2025. The company also received a $10 million milestone payment from Boehringer Ingelheim.
Surrozen's progress in clinical trials and new preclinical candidates enhances growth potential, while the $10 million milestone boosts financial stability, signaling positive momentum for investors.
Surrozen, Inc. has entered a research collaboration with TCGFB, Inc. to develop antibody therapeutics targeting TGF-ฮฒ for idiopathic pulmonary fibrosis (IPF) treatment.
The collaboration between Surrozen and TCGFB could enhance Surrozen's pipeline and market position in fibrosis treatments, potentially boosting investor confidence and company valuation.
Surrozen, Inc. (Nasdaq: SRZN) announced that CEO Craig Parker will present at two healthcare investor conferences, focusing on their targeted therapeutics for tissue repair.
Surrozen's CEO presenting at healthcare conferences signals potential investor interest and visibility, which may impact stock performance and market perception of the company's growth prospects.
Boehringer Ingelheim is advancing SZN-413, a bi-specific antibody targeting Fzd4 for retinal vascular diseases, towards future clinical testing, as announced by Surrozen, Inc. on Sept. 24, 2024.
Boehringer's advancement of SZN-413 for retinal diseases signals potential breakthroughs in treatment, impacting Surrozen's stock value and future revenue prospects.
Surrozen, Inc. is conducting a Phase 1b trial for SZN-043 targeting Severe Alcoholic Hepatitis and reported Phase 1a data. The company also shared Q2 2024 financial results and updates.
Surrozen's advancement in clinical trials for Severe Alcoholic Hepatitis and innovative technologies could enhance its market position, potentially impacting stock performance and investor sentiment.
Surrozen's SZN-043, a novel biotherapeutic, showed safety and efficacy in Phase 1a trials for liver cirrhosis. Enrollment continues in a Phase 1b study for severe alcohol-associated hepatitis.
SZN-043 shows promise in treating liver conditions, with safe Phase 1a results. Positive outcomes may boost Surrozen's stock and market position in biotherapeutics for liver diseases.
Frequently Asked Questions About SRZN Stock
What is Surrozen, Inc.'s (SRZN) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Surrozen, Inc. (SRZN) has a median price target of $38.50. The highest price target is $45.00 and the lowest is $32.00.
Is SRZN stock a good investment in 2025?
According to current analyst ratings, SRZN has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for SRZN stock?
Wall Street analysts predict SRZN stock could reach $38.50 in the next 12 months. This represents a 285.0% increase from the current price of $10.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Surrozen, Inc.'s business model?
Surrozen, Inc. operates as a clinical stage biotechnology firm focused on discovering and developing drug candidates that modulate the Wnt pathway for tissue repair. The company generates revenue through collaborations and licensing agreements, such as its partnership with Boehringer Ingelheim, while advancing its own pipeline of antibody-based therapeutics targeting various diseases.
What is the highest forecasted price for SRZN Surrozen, Inc.?
The highest price target for SRZN is $45.00 from Yatin Suneja at Guggenheim, which represents a 350.0% increase from the current price of $10.00.
What is the lowest forecasted price for SRZN Surrozen, Inc.?
The lowest price target for SRZN is $32.00 from Matthew Caufield at HC Wainwright & Co., which represents a 220.0% increase from the current price of $10.00.
What is the overall SRZN consensus from analysts for Surrozen, Inc.?
The overall analyst consensus for SRZN is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $38.50.
How accurate are SRZN stock price projections?
Stock price projections, including those for Surrozen, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.